These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25393253)

  • 1. Expression of multidrug resistance 1 gene in association with CXCL12 in chronic myelogenous leukaemia.
    Onishi I; Nakagawa Y; Murayama T; Hidaka M; Yamamoto K; Abe-Suzuki S; Abe S; Kurata M; Kitagawa M
    Pathology; 2014 Dec; 46(7):623-9. PubMed ID: 25393253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
    Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
    Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
    Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
    Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.
    Galimberti S; Cervetti G; Guerrini F; Testi R; Pacini S; Fazzi R; Simi P; Petrini M
    Cancer Genet Cytogenet; 2005 Oct; 162(1):57-62. PubMed ID: 16157201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
    Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
    Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.
    Li W; Ding Q; Ding Y; Lu L; Wang X; Zhang Y; Zhang X; Guo Q; Zhao L
    Mol Carcinog; 2017 Mar; 56(3):863-876. PubMed ID: 27533597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
    Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
    Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
    Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
    Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy.
    Sayed D; Badrawy H; Gaber N; Khalaf MR
    Leuk Res; 2014 Feb; 38(2):243-50. PubMed ID: 24374144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
    Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
    Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression.
    Benito R; Lumbreras E; Abáigar M; Gutiérrez NC; Delgado M; Robledo C; García JL; Rodríguez-Vicente AE; Cañizo MC; Rivas JM
    Pharmacogenet Genomics; 2012 May; 22(5):381-8. PubMed ID: 22388797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
    Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
    Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.